Recent News
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (BEAT-meso)
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.
Acupuncture as Potential Palliative Care for Mesothelioma Patients
When one thinks of acupuncture, one may envision a nice relaxing trip to a day spa, where after a long massage or a relaxing facial, tension in body can be…
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
Quality of Life After Pleurectomy/Decortication vs. Extra Pleural Pneumonectomy
On the rare instance that mesothelioma is diagnosed in the early stages of the disease, patients have the option for surgery. There are several surgical procedures used to treat mesothelioma.…
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
Phase 1 Clinical Trial For Those With Peritoneal Mesothelioma Underway
Mesothelioma is a rare cancer affecting only about 3,000 Americans each year. Most of those diagnosed are diagnosed with pleural mesothelioma, but a small number (approx. 500 per year) are…
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, two-part phase 1 trial of INBRX-109, which is a recombinant humanized multivalent antibody targeting the human death receptor 5 (DR5).
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)
Primary Outcome Measures Overall Survival [ Time Frame: 60 months ] Time to death (from any cause) from randomization Secondary Outcome Measures Survival rate [ Time Frame: 60 months ]…
Decade Long Study Reveals Potential for Early Detection in Mesothelioma
For many patients who are suffering from malignant mesothelioma, their diagnosis came quickly after experiencing symptoms. In many cases, this is because symptoms of mesothelioma typically do not appear until…
Researchers Theorize Drug from the 1800s Could Improve Radiation Treatments in Mesothelioma Patients
Radiation therapy for those suffering from mesothelioma is not typically the first line of treatment because of its overall effectiveness. High-energy x-rays, gamma rays, and neutrons that make up radiation…
